APA (7th ed.) Citation

J, W., MD, M., K, B., AM, B., S, A., T, C., . . . G, B. (2024). Phase I/II study of the clinical activity and safety of GSK3326595 in patients with myeloid neoplasms. Therapeutic advances in hematology, 15, 20406207241275376. https://doi.org/10.1177/20406207241275376

Chicago Style (17th ed.) Citation

J, Watts, et al. "Phase I/II Study of the Clinical Activity and Safety of GSK3326595 in Patients with Myeloid Neoplasms." Therapeutic Advances in Hematology 15 (2024): 20406207241275376. https://doi.org/10.1177/20406207241275376.

MLA (9th ed.) Citation

J, Watts, et al. "Phase I/II Study of the Clinical Activity and Safety of GSK3326595 in Patients with Myeloid Neoplasms." Therapeutic Advances in Hematology, vol. 15, 2024, p. 20406207241275376, https://doi.org/10.1177/20406207241275376.